Skip to main content. Anticipate submitting New Drug Application in early assuming successful completion of additional non clinical work and month long-term stability data. Acer Therapeutics Inc. Nasdaq: ACERa pharmaceutical company focused on the Comoany, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced full enrollment of Part A in a pivotal trial evaluating bioavailability and bioequivalence of ACER for the treatment of Urea Cycle Disorders UCDs.

Acer intends to use the net proceeds from this offering to fund Acer Pharmaceutical Company research and development efforts, to seek regulatory approval for EDSIVO. The month of February ended with a flurry of clinical trial announcements. Heading Acer Pharmaceutical Company the holidays, there was still plenty of clinical trial news last week.

It was a typically busy week. July looks to be a quiet month for the U. Food and Drug Administration FDAand it sure looks Companu the agency is trying to get a lot of work done before the July 4 Hatch Company. Acer Therapeutics, headquartered in Newton, Mass. First 1 2 Next Last.

Home - Acer Therapeutics

Acer is committed to supporting patients and families that need it most. PIPELINE. We are developing ACER-001. The first potential therapy for Maple Syrup Urine Disease (MSUD); and the Urea Cycle Disorder (USD) LEARN MORE. Acer is changing the path ……

Pipeline - Acer Therapeutics

Acer is a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs. Acer’s pipeline includes three clinical-stage candidates: EDSIVO™ (celiprolol) for the treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients with a confirmed type III collagen (COL3A1 ...…

ACER - Acer Therapeutics Inc. • BioPharmCatalyst

NewsSee all news. 24 February 2020 Acer Therapeutics Announces ACER-001 for Urea Cycle Disorders Trial Shows Bioequivalence to BUPHENYL®. NEWTON, Mass., Feb. 24, 2020 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (NASDAQ:ACER), a pharmaceutical company focused on the acquisition, development, and commercialization of therapies for serious rare and…